Amgen Inc. (NASDAQ:AMGN) Shares Sold by Groupama Asset Managment

Groupama Asset Managment decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 14.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 17,480 shares of the medical research company’s stock after selling 3,054 shares during the quarter. Groupama Asset Managment’s holdings in Amgen were worth $4,533,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Centricity Wealth Management LLC purchased a new position in Amgen in the 4th quarter worth approximately $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen during the third quarter valued at approximately $29,000. Synergy Investment Management LLC acquired a new position in shares of Amgen during the fourth quarter worth $34,000. Atala Financial Inc purchased a new position in shares of Amgen in the fourth quarter valued at $34,000. Finally, Heck Capital Advisors LLC acquired a new stake in Amgen during the 4th quarter valued at $36,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

AMGN stock opened at $306.92 on Wednesday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The stock has a market capitalization of $164.88 billion, a price-to-earnings ratio of 40.65, a PEG ratio of 2.63 and a beta of 0.53. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The stock’s fifty day moving average is $302.51 and its two-hundred day moving average is $297.63.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio (DPR) is 126.09%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on AMGN shares. Piper Sandler upped their price objective on shares of Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Piper Sandler Companies restated an “overweight” rating and set a $310.00 price objective on shares of Amgen in a research note on Thursday, January 2nd. Wells Fargo & Company restated an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $324.00 price target on shares of Amgen in a report on Friday, January 24th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $314.04.

Insider Activity at Amgen

In related news, EVP Jonathan P. Graham sold 25,045 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares of the company’s stock, valued at $8,496,669.44. This represents a 46.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the firm’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the transaction, the executive vice president now directly owns 36,922 shares in the company, valued at approximately $11,240,533.68. The trade was a 40.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock worth $20,644,335 in the last three months. 0.69% of the stock is owned by company insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.